|
You are here: Home: BCU 7|2003: Faculty
disclosures
FACULTY DISCLOSURES
As a provider accredited by the ACCME, it is the policy of NL
Communications to require the disclosure of any significant financial
interest or any other relationship the sponsor or faculty members
have with the manufacturer(s) of any commercial product(s) discussed
in an educational presentation. The presenting faculty reported
the following:
Howard A Burris III, MD |
Grants/Research Support: Bristol-Myers
Squibb Company, Aventis Pharmaceuticals, GlaxoSmithKline,
Genentech Inc, Eli Lilly & Company,
Roche Laboratories Inc
Consultant: Bristol-Myers Squibb Company,
Aventis Pharmaceuticals, Genentech Inc
Honorarium: Bristol-Myers Squibb Company, Aventis Pharmaceuticals,
Genentech Inc, GlaxoSmithKline, Eli Lilly & Company |
Richard M Elledge,
MD |
Grants/Research Support: AstraZeneca Pharmaceuticals LP,
Aventis Pharmaceuticals, Genentech, Inc |
Rowan T Chlebowski, MD, PhD
|
Consultant: AstraZeneca Pharmaceuticals LP, Eli Lilly & Company
Honorarium: AstraZeneca Pharmaceuticals LP, Eli Lilly & Company |
Vicente Valero, MD |
No financial interests or affiliations to disclose |
| Pharmaceutical agents discussed in this program: |
| G E N E R I C |
T R A D E |
M A N U F A C T U R E R |
| anastrozole |
Arimidex® |
AstraZeneca Pharmaceuticals LP |
| capecitabine |
Xeloda® |
Roche Laboratories Inc |
| carboplatin |
Paraplatin® |
Bristol-Myers Squibb Company |
| cisplatin |
Platinol® |
Bristol-Myers Squibb Company |
| cyclophosphamide |
Cytoxan® |
Bristol-Myers Squibb Company |
| |
Neosar® |
Pfizer Inc |
| docetaxel |
Taxotere® |
Aventis Pharmaceuticals Inc |
| doxorubicin |
Adriamycin® |
Pfizer Inc |
| estradiol |
Various |
Various |
| etoposide, VP-16 |
Vepesid® |
Bristol-Myers Squibb Company |
| exemestane |
Aromasin® |
Pfizer Inc |
| filgrastim |
Neupogen® |
Amgen Inc |
| fulvestrant |
Faslodex® |
AstraZeneca Pharmaceuticals LP |
| gefitinib |
Iressa® |
AstraZeneca Pharmaceuticals LP |
| goserelin |
Zoladex® |
AstraZeneca Pharmaceuticals LP |
| letrozole |
Femara® |
Novartis Pharmaceuticals Corporation |
| conjugated estrogen/ |
PremproT |
Wyeth Pharmaceuticals Inc |
| medroxyprogesterone acetate |
|
|
| paclitaxel |
Taxol® |
Bristol-Myers Squibb Company |
| tamoxifen citrate |
Nolvadex® |
AstraZeneca Pharmaceuticals LP |
| triptorelin |
Various |
Various |
| trastuzumab |
Herceptin® |
Genentech Inc |
| zoledronic acid/zoledronate |
Zometa® |
Novartis Pharmaceuticals Corporation |
This educational activity contains discussion of published and/or
investigational uses of agents that are not indicated by the Food
and Drug Administration. NL Communications does not recommend the
use of any agent outside of the labeled indications. Please refer
to the official prescribing information for each product for discussion
of approved indications, contraindications and warnings. The opinions
expressed are those of the presenters and are not to be construed
as those of the publisher or grantor.
|
|
|
|
